External validation of AF-BLEED for predicting major bleeding and for tailoring NOAC dose in AF patients: A post hoc analysis in the ENGAGE AF-TIMI 48

AF-BLEED, a simple bleeding risk classifier, was found to predict major bleeding (MB) in patients with atrial fibrillation (AF) and identify AF patients at high risk of MB who might potentially benefit from a lower direct oral anticoagulant dose. This post hoc study aimed to externally validate these findings in the ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor Xa next Generation in Atrial Fibrillation –Thrombolysis in Myocardial Infarction study 48) trial.

Source: Thrombosis Research - August 1, 2023 Category: Hematology Authors: G. Chu, L. Valerio, S. Barco, M.V. Huisman, S.V. Konstantinides, F.A. Klok Tags: Full Length Article Source Type: research